- Home
- ANGO vs EYPT Comparison
ANGO vs EYPT Comparison
Compare ANGO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | EYPT |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 419.9M |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ANGO | EYPT |
|---|---|---|
| Price | $15.87 | $4.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $18.00 | ★ $31.80 |
| AVG Volume (30 Days) | 395.6K | ★ 5.9M |
| Earning Date | 04-02-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $291,010,000.00 | $7,539,000.00 |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $9.39 | $3.95 |
| 52 Week High | $16.29 | $19.11 |
Technical Indicators
Market Signals| Indicator | ANGO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 28.47 |
| Support Level | $10.56 | $3.95 |
| Resistance Level | $16.20 | $15.17 |
| Average True Range (ATR) | 0.43 | 0.64 |
| MACD | -0.10 | -0.47 |
| Stochastic Oscillator | 47.66 | 5.04 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.